Home >
Publications/Products > HIV/Hepatitis C Coinfection Guidelines
for Health Care Providers
Table 9. Virologic Response Rates in the RIBAVIC Study
Back to Management and Treatment of Hepatitis C Virus Infection in HIV-Infected Adults
| INF alfa-2b 3 MIU. tiw x 48 wk + RBV 800 mg/day x 48 wk | Peg INF alfa-2b (PEG-INTRON) 1.5 µg/kg per week + RBV 800 mg/day x 48 wk | |
|---|---|---|
| *p = 0.031 versus INF + RVB; NR = not reported. | ||
| n = 207 | n = 205 | |
| ETR (Overall) | NR | 37% |
| Genotype 1 | NR | NR |
| Genotype 2,3 | NR | NR |
| SVR (Overall) | 15% | 27%* |
| Genotype 1 | 5% | 15% |
| Genotype 2,3 | 40% | 46% |
From Management and Treatment of Hepatitis C Virus Infection in HIV-Infected Adults
Hepatitis C Resource Center Program and National Hepatitis C Program Office
September 2005
